NovaBay Pharmaceuticals: Funding, Investors & Team (Sep 2026)

Going Beyond Antibiotics® Developing Anti-Infective Compounds Effective Against Bacteria, Viruses and Fungi. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States. Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. Avenova with Neutrox removes debris from the skin on eyelids and lashes without burning or stinging. We have developed additional commercial products containing Neutrox, including our NeutroPhase® Skin and Wound Cleanser for wound care and CelleRx® for the dermatology market. We have partnerships for NeutroPhase in the U.S. as well as select overseas markets, most notably China. In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.

NovaBay Pharmaceuticals has raised $5.3M across 1 round on record. The most recent is a Post-IPO Equity of $5.3M announced in Sep 2022.

NovaBay Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $5.3M, announced in Sep 2022.

Mark Sieczkarek is listed as CEO at NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals is based in Emeryville, California, United States.

NovaBay Pharmaceuticals is in the 101-250 employee band.

NovaBay Pharmaceuticals' latest round of $5.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.